Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by RWA Wealth Partners LLC

RWA Wealth Partners LLC grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,204 shares of the biopharmaceutical company’s stock after acquiring an additional 250 shares during the quarter. RWA Wealth Partners LLC’s holdings in Gilead Sciences were worth $2,690,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Tompkins Financial Corp increased its holdings in shares of Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the last quarter. OFI Invest Asset Management bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $26,000. Fortitude Family Office LLC bought a new position in Gilead Sciences during the 4th quarter worth $29,000. Rakuten Securities Inc. bought a new position in Gilead Sciences during the 4th quarter worth $33,000. Finally, Financial Connections Group Inc. bought a new position in Gilead Sciences during the 4th quarter worth $40,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Mizuho lowered their price objective on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research note on Thursday, February 22nd. Wells Fargo & Company lowered their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research note on Monday, March 4th. Barclays reduced their price target on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research report on Monday, February 12th. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and reduced their price target for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Finally, StockNews.com lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 19th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $84.71.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the sale, the insider now directly owns 100,936 shares of the company’s stock, valued at $7,386,496.48. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.29% of the stock is currently owned by company insiders.

Gilead Sciences Trading Up 0.1 %

Shares of Gilead Sciences stock opened at $67.03 on Wednesday. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The firm has a market cap of $83.46 billion, a price-to-earnings ratio of 14.90, a price-to-earnings-growth ratio of 0.96 and a beta of 0.19. The business has a fifty day simple moving average of $71.68 and a 200-day simple moving average of $76.46. Gilead Sciences, Inc. has a fifty-two week low of $65.90 and a fifty-two week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. During the same period in the prior year, the company earned $1.67 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post 6.28 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.59%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.